Browse the corpus

Galantamine is an acetylcholinesterase inhibitor used to manage Alzheimer disease by elevating acetylcholine levels in the brain, thereby improving cognitive function and memory. This activity reviews galantamine's indications, mechanism of action, contraindications, and adverse events. Additionally, essential considerations will be discussed, including dosing guidelines, pharmacokinetics, pharmacodynamics, potential drug-drug interactions, and necessary monitoring strategies. Special attention is given to warnings associated with galantamine and identifying specific patient populations where galantamine should be prescribed cautiously. This session provides healthcare professionals with the knowledge required to customize treatment plans effectively, enhancing therapeutic outcomes for patients with dementia, particularly those with Alzheimer disease. Emphasis is placed on the integral role of the interprofessional healthcare team in managing and supervising galantamine therapy to optimize patient care. Objectives: Identify the proposed mechanism of action of galantamine therapy. Differentiate the common galantamine formulations. Assess the most frequently encountered adverse events associated with galantamine therapy. Evaluate the importance of interprofessional coordination and communication for patients on galantamine therapy. Access free multiple choice questions on this topic.

Signs and Symptoms of Overdose As in any overdose case, general supportive therapy should be provided. Since the policies for the management of drug overdose are continually advancing, it is advisable to consult a poison control center for the latest recommendations for managing galantamine overdose. The clinical picture of a significant galantamine overdose is similar to an overdose on other cholinergic medications. These effects involve the neuromuscular junction, parasympathetic, and central nervous systems. An overdose of galantamine produces a syndrome of cholinergic crisis. In addition to muscle weakness or fasciculations, the patient may present with some or all the following symptoms and signs: salivation, severe nausea, vomiting, abdominal cramping, sweating, lacrimation, urination, defecation, bradycardia, hypotension, depression of respiration, collapse, and convulsions. Death may occur if worsening muscle weakness involves respiratory muscles. Management of Overdose Atropine is a tertiary anticholinergic that may be used as an antidote for galantamine overdose. Atropine sulfate is administered intravenously and is recommended at a starting dose of 0.5 mg to 1.0 mg, with subsequent doses given based on clinical response. Atypical blood pressure and heart rate responses have been observed when other cholinergic agents and tertiary anticholinergics are concurrently administered. Dialysis (hemodialysis, peritoneal dialysis, hemofiltration) may effectively remove galantamine or its metabolites.[50] Non-clinical Toxicology Carcinogenesis: In a 2-year oral carcinogenicity study in rats, a surge in endometrial adenocarcinomas was seen at 10 mg/kg/d (6 times on a plasma exposure (AUC) basis or 4 times the MRHD of 24 mg daily on an mg/m basis) and 30 mg/kg/d (19 times on an AUC basis or 12 times MRHD on an mg/m basis). Mutagenesis: Galantamine was negative in a battery of in vitro and in vivo genotoxicity assays conducted in bacteria, mice, and mammalian cells Impairment of fertility: No impairment of fertility occurred in rats when galantamine was given up to 16 mg/kg/d (7 times the MRHD on a mg/m basis) for 14 days and 60 days before mating in females and males, respectively.

Galantamine, a cholinomimetic agent, is used to treat patients with dementia associated with Alzheimer disease. Primary care providers and neurologists prescribe galantamine. However, properly managing patients on galantamine therapy requires collaboration and open communication among interprofessional healthcare team members. The patient and family should be counseled that galantamine is a symptomatic treatment and does not modify the underlying disease process and progression. Galantamine alleviates the symptoms of dementia by improving cognition, global functioning, daily life activity, and behavior. Clinicians should regularly follow up with the patient to gradually titrate the dosage and assess the efficacy and safety of the dose to the patient. Patients and caregivers should be advised to stop the medication immediately upon the appearance of skin rash or other manifestations of hypersensitivity and seek professional assistance immediately. Polypharmacy and drugs causing cognitive impairment should be avoided when possible. Consultation with the pharmacist, checking for drug-to-drug interaction, and performing medication reconciliation are beneficial in verifying the dosage and schedule of galantamine. If the pharmacist detects any issue, it should be reported to the prescribers. Nurses should be familiar with the adverse event profile of galantamine as they are the health professionals who first encounter these patients during follow-up visits and assisted living facilities. Nurses educate the patient and family regarding the importance of adequate fluid intake and taking medication with meals. The emergency room staff and all clinicians, including primary care and specialists, should be trained to manage toxicity due to overdosage and other life-threatening adverse effects. Patients, families, and caregivers should understand the condition's progressive nature and have realistic expectations from the treatment. They should be educated about unpleasant effects and contact information for poison control centers. An interprofessional team approach is essential during galantamine therapy to achieve an optimal patient outcome.